Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Change in Account Payables (2023 - 2025)

Immunome's Change in Account Payables history spans 3 years, with the latest figure at -$2.3 million for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 124.56% year-over-year to -$2.3 million; the TTM value through Dec 2025 reached -$9.2 million, down 196.2%, while the annual FY2025 figure was -$9.2 million, 196.2% down from the prior year.
  • Change in Account Payables reached -$2.3 million in Q4 2025 per IMNM's latest filing, down from $1.9 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $9.3 million in Q4 2024 to a low of -$4.9 million in Q2 2025.
  • Average Change in Account Payables over 3 years is -$20500.0, with a median of -$355500.0 recorded in 2023.
  • Peak YoY movement for Change in Account Payables: skyrocketed 1465.24% in 2024, then crashed 15362.5% in 2025.
  • A 3-year view of Change in Account Payables shows it stood at -$679000.0 in 2023, then surged by 1465.24% to $9.3 million in 2024, then crashed by 124.56% to -$2.3 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Change in Account Payables are -$2.3 million (Q4 2025), $1.9 million (Q3 2025), and -$4.9 million (Q2 2025).